Risk factors
LENZ Therapeutics (LENZ) risk factors
Item 1A of every LENZ Therapeutics, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
53 risks, 9 new, 12 dropped, 13 reworded since the prior year. LENZ transitioned from a clinical-stage biotech to a commercial-stage company following FDA approval and U.S. launch of VIZZ for presbyopia.
Filed Mar 24, 2026 - FY2024 10-K risk factors
56 risks. LENZ Therapeutics relies entirely on the success of LNZ100 for presbyopia, pending FDA review of its NDA submitted in August 2024. The company depends on third-party manufacturers, international partners like CORXEL in Greater China, and robust intellectual property protection for aceclidine.
Filed Mar 19, 2025